The FDA also changed Ixchiq’s indication to include adults 18 years and older who are high risk of exposure to chikungunya. Previously, the label prescribed use in adults who are at increased ...

Yes, and you might be surprised to learn that it’s a fairly recent development. In 2023, the FDA approved Ixchiq, the first vaccine against chikungunya, for adults 18 and older.

Class-wide label change for opioids; positive results for oral GLP-1; migraine prevention therapy approved for children; FDA removes restriction on Ixchiq for older adults; Modeyso approved for ...

In late 2023, the FDA also approved a vaccine for chikungunya for people over the age of 18 who are at increased risk of exposure to the virus called IXCHIQ.

Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use ...

July 11 (Reuters) - The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s (VLS.PA) chikungunya vaccine, Ixchiq, in adults aged 65 ...

In addition to Brazil, IXCHIQ ® is approved for the prevention of disease caused by the chikungunya virus in people aged 12 years and older in the EU, and in people aged 18 years and older in the ...

With this U.S. approval, IXCHIQ ® becomes the world’s first licensed chikungunya vaccine available to address this unmet medical need and the third vaccine Valneva 1 has brought from early R&D ...